In an interesting randomized clinical trial (RCT), Donnino et al. \[[@CR1]\] studied a mixed out-of-hospital cardiac arrest and in-hospital cardiac arrest (IHCA) population and found no hydrocortisone versus placebo hemodynamic or in-hospital outcome benefit. In the hydrocortisone group, the median time to study intervention was 9.9 h after return of spontaneous circulation (ROSC) \[[@CR1]\]. This time lag probably exceeds the therapeutic window for the prevention of detrimental episodes of early post-resuscitation hypotension \[[@CR2]\] through a mean arterial pressure (MAP)-stabilizing effect of steroids \[[@CR3], [@CR4]\].

Analyses of pooled post-resuscitation shock data from our IHCA vasopressin-steroids-epinephrine (VSE) RCTs \[[@CR3], [@CR4]\] also showed no between-group differences in the time to, or proportions of, discontinuation of vasopressors, and post-ROSC day 1 hemodynamic support (Table [1](#Tab1){ref-type="table"}). However, VSE patients had higher, early post-ROSC systolic arterial pressure (SAP) and MAP during post-resuscitation follow-up \[[@CR3], [@CR4]\]. This reflected an improved hemodynamic response to similar vasopressor support titrated to a "wide" MAP range of 70--100 mmHg \[[@CR4]\].Table 1Pooled results (from \[[@CR3]\] and \[[@CR4]\]) on early post-enrollment hemodynamics in survivors for ≥4 h with post-resuscitation shockSurvivors for ≥4 h with post-resuscitation shock^a^VSE group (*n* = 103)Control group (*n* = 88)*P* valueTime to discontinuation of vasopressors (days), median (IQR)^b^4 (2--8)3 (2--6)0.86Discontinuation of vasopressors during follow-up, *n* (%)43 (41.7)34 (38.6)0.77Estimated cumulative vasopressor dose (μg/kg) over the first 24 h post-ROSC, median (IQR)^c,d,e^552 (216--1225)629 (321--1236) (*n* = 87)0.15Cumulative 24-h post-ROSC fluid balance (mL), mean ± SD2168 ± 2398 (*n* = 78)2034 ± 2198 (*n* = 60)0.74SAP \>90 mmHg within 15--20 min post-ROSC, *n* (%)76 (80.9) (*n* = 94)40 (55.6) (*n* = 72)0.001At least 1 recorded/analyzed MAP value \>80 mmHg over day 1, *n* (%)82 (80.4) (*n* = 102)35 (42.2) (*n* = 83)\<0.001ALS duration (min), median (IQR)10 (6--16)12 (6--20)0.11SAP \>90 mmHg (*n* = 116)SAP ≤90 mmHg (*n* = 50)*P* valueSurvival to hospital discharge with CPC score of 1 or 2, *n* (%)23 (19.8)3 (6.0)0.02MAP \>80 mmHg (*n* = 117)MAP ≤80 mmHg (*n* = 68)*P* valueSurvival to hospital discharge with CPC score of 1 or 2, *n* (%)25 (21.4)4 (5.9)0.006Data reported as *n* (%) were analyzed with the Fisher's exact test; data reported as median (IQR) were analyzed with the Mann-Whitney exact *U* test; and data reported as mean ± SD were analyzed with the independent samples *t* test^a^Defined as sustained (\>4 h), new post-arrest circulatory failure or post-arrest need for ≥50 % increase in any pre-arrest vasopressor/inotropic support targeted to MAP \>70 mmHg \[[@CR3], [@CR4]\]^b^Defined as number of days from study enrollment until the first circulatory failure-free day; the latter corresponds to a sequential organ failure assessment (SOFA) circulatory subscore \<3; in both studies \[[@CR3], [@CR4]\], the SOFA score was determined daily through follow-up days 1--60 post-randomization^c^With respect to \[[@CR3]\]: average daily infusion rates (IRs) of vasopressors were already available as they were calculated by the investigators who conducted the follow-up; corresponding results were reported in the supplement of the originally published article. Consequently, Day 1 dose of a vasopressor (VD) (μg/kg) = average daily IR (μg/kg/min) × 1440 (min)^d^With respect to \[[@CR4]\]: for patients with IR data (μg/kg/min) available at 20 min post-ROSC (IR20M), 4 h post-ROSC (IR4H), and 24 h post-ROSC (IR24H) (*n* = 108), VD (μg/kg) was estimated as follows: VD = average (IR20M; IR4H) × 240 (min) + average (IR4H; IR24H) × 1200 (min). For patients with available IR20M and IR4H (*n* = 39), VD (μg/kg) was estimated as follows: VD = average (IR20M; IR4H) × 240 (min) + IR4H × (number of min until death after the completion of 4-h survival). For patients with available IR20M only (*n* = 1), VD (μg/kg) was estimated as follows: VD = IR20M × (number of min until death)^e^For both \[[@CR3]\] and \[[@CR4]\], total day 1 VD (μg/kg) was calculated as follows \[[@CR1]\]: VD = norepinephrine (μg/kg) + dopamine/2 (μg/kg) + epinephrine (μg/kg)*ALS* advanced life support, *CPC* cerebral performance category, *IQR* interquartile range, *MAP* mean arterial pressure, *ROSC* return of spontaneous circulation, *SAP* systolic arterial pressure, *SD* standard deviation, *VSE* vasopressin-steroids-epinephrine

Recordings of "early post-ROSC SAP \>90 mmHg" (i.e., "absence of early post-resuscitation hypotension" \[[@CR2]\]) and "≥1 recorded/analyzed, day 1 MAP value of \>80 mmHg \[[@CR2]\]" were significantly more frequent in VSE patients than controls. Importantly, such SAP/MAP levels corresponded to more frequent survival to hospital discharge with favorable neurological outcome \[[@CR4]\] (Table [1](#Tab1){ref-type="table"}).

Early post-resuscitation hemodynamics of VSE patients could be partly attributable to the steroids-vasopressin combination during cardiopulmonary resuscitation (CPR) \[[@CR3], [@CR4]\]. However, a previously postulated major CPR-VSE effect, i.e., shorter advanced life support duration \[[@CR4]\], possibly leading to attenuated post-resuscitation cardiovascular dysfunction was not clear in the current subgroup analysis (Table [1](#Tab1){ref-type="table"}). Hence, according to the short (i.e., 24 min) half-life of vasopressin, we propose that the more frequent day 1 MAP \>80 mmHg was largely due to a post-ROSC steroid-induced augmentation of vascular responsiveness to vasopressors \[[@CR3], [@CR4]\]. A mediation analysis of VSE outcome benefit through day 1 MAP is warranted. Analysis of day 1 MAP data from the study by Donnino et al. might causally link between-RCT differences in corticosteroid timing with differences in survival/neurological outcome results \[[@CR1], [@CR3], [@CR4]\].

Post-resuscitation disease is a "sepsis-like" syndrome. In sepsis, acute kidney injury severity is associated with mortality and elevated interleukin (IL)-6. Furthermore, high post-ROSC IL-6 is associated with organ dysfunction and poor long-term outcomes \[[@CR5]\]. Notably, post-resuscitation hydrocortisone has been associated with reduced IL-6 levels \[[@CR1], [@CR3]\], and VSE patients versus controls had more renal failure-free days \[[@CR3], [@CR4]\].

Conclusively, available evidence prompts toward further evaluation of early, stress-dose steroids in cardiac arrest.
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See related research by Donnino et al., <http://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1257-x>

For the purpose of the above-mentioned re-analysis protocol (Clinicaltrials.gov identifier, NCT02408939), we extracted individual peri-arrest and follow-up data from survivors for ≥4 h with post-resuscitation shock (*n* = 191) from an electronic masterfile containing de-identified data from references \[[@CR3]\] and \[[@CR4]\]. Extracted, de-identified data was saved in a Microsoft Excel datafile. Data will not be shared because we plan to use it in a future mediation analysis mentioned in the fourth paragraph of the current main text.
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